Paper41282147
Calcitriol and hyperthermia potentiate gemcitabine efficacy - A Multifactorial Preclinical Evaluation in Pancreatic and Breast Cancer.
Wiecheć-Cudak O and 10 others. Res Sq, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Calcitriol and hyperthermia potentiate gemcitabine efficacy - A Multifactorial Preclinical Evaluation in Pancreatic and Breast Cancer. Papers, record 41282147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41282147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Calcitriol and hyperthermia potentiate gemcitabine efficacy - A Multifactorial Preclinical Evaluation in Pancreatic and Breast Cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AR073004 | NIAMS NIH HHS | United States | R01AR073004 | PubMed and NIH |
Source NIH RePORTER
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20138989 | Heat shock protein 90 interacts with vitamin D receptor in human leukemia cells. | J Steroid Biochem Mol Biol | 2010 | https://conductscience.org/library/papers/20138989 | PubMed |
| 2 | 28885916 | Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells. | J Pharm Pharm Sci | 2017 | https://conductscience.org/library/papers/28885916 | PubMed |
| 3 | 28410237 | Combination therapy in combating cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28410237 | PubMed |
| 4 | 15681024 | Overcoming limitations of natural anticancer drugs by combining with artificial agents. | Trends Pharmacol Sci | 2005 | https://conductscience.org/library/papers/15681024 | PubMed |
| 5 | 26949479 | Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. | Comput Struct Biotechnol J | 2015 | https://conductscience.org/library/papers/26949479 | PubMed |
| 6 | 40416168 | Targeting ERβ1-Positive Triple-Negative Breast Cancer: Molecular Effects of Calcitriol and 17β-Estradiol. | Cureus | 2025 | https://conductscience.org/library/papers/40416168 | PubMed |
| 7 | 22594894 | New vitamin D analogs as potential therapeutics in melanoma. | Expert Rev Anticancer Ther | 2012 | https://conductscience.org/library/papers/22594894 | PubMed |
| 8 | 25558828 | A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. | Cell Cycle | 2014 | https://conductscience.org/library/papers/25558828 | PubMed |
| 9 | 27865536 | Breast cancer. | Lancet | 2017 | https://conductscience.org/library/papers/27865536 | PubMed |
| 10 | 38927967 | Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38927967 | PubMed |
| 11 | 15585396 | Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. | J Gastrointest Surg | 2004 | https://conductscience.org/library/papers/15585396 | PubMed |
| 12 | 29763773 | Ultrasound Doppler as an Imaging Modality for Selection of Murine 4T1 Breast Tumors for Combination Radiofrequency Hyperthermia and Chemotherapy. | Transl Oncol | 2018 | https://conductscience.org/library/papers/29763773 | PubMed |
| 13 | 22690925 | Old and new facts about hyperthermia-induced modulations of the immune system. | Int J Hyperthermia | 2012 | https://conductscience.org/library/papers/22690925 | PubMed |
| 14 | 20164683 | Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. | Cancer J | 2010 | https://conductscience.org/library/papers/20164683 | PubMed |
| 15 | 31892603 | Relevance of Vitamin D in Melanoma Development, Progression and Therapy. | Anticancer Res | 2020 | https://conductscience.org/library/papers/31892603 | PubMed |
| 16 | 30968156 | Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line. | Int J Oncol | 2019 | https://conductscience.org/library/papers/30968156 | PubMed |
| 17 | 28676457 | On the role of classical and novel forms of vitamin D in melanoma progression and management. | J Steroid Biochem Mol Biol | 2018 | https://conductscience.org/library/papers/28676457 | PubMed |
| 18 | 21160030 | 20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. | Am J Physiol Cell Physiol | 2011 | https://conductscience.org/library/papers/21160030 | PubMed |
| 19 | 26445902 | Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland. | Sci Rep | 2015 | https://conductscience.org/library/papers/26445902 | PubMed |
| 20 | 23662149 | Hyperthermia versus Oncothermia: Cellular Effects in Complementary Cancer Therapy. | Evid Based Complement Alternat Med | 2013 | https://conductscience.org/library/papers/23662149 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41282147
GET https://conductscience.org/api/papers/v1/41282147/references?page=2